No Data
Intense competition in CRO has reduced gross margin. Sunlight Nuohe is entering the animal health field to seek new growth points.
① Sunshine Nuohuo has experienced growth in revenue and net income in the first three quarters of this year compared to previous years, but intense competition in the industry has led to a decline in gross margin, and the chairman revealed that the company is increasing its investment in research and development. ② To seek new growth points, Sunshine Nuohuo is expanding its CRO business from the human pharmaceutical field to the animal health field by establishing subsidiaries, and has signed service orders with several medium and large animal pharmaceutical companies.
Sunshine Nuohuo (688621.SH): Has not yet entered the field of CDMO contract manufacturing services.
On November 19th, Guang Longhui reported that Sunshine Nuohuo (688621.SH) stated on the investor interaction platform that the products independently developed and reserved by the company are transferred before and after obtaining clinical trial approvals, and subsequent services are also locked in. Currently, the company has not entered the CDMO contract manufacturing service field, so this system does not have a significant impact on the company's operation. In addition, this type of draft for comments will go through a period of public consultation before formal issuance.
Sunshine Novo: Third Quarter Report 2024
Third Quarter Report 2024
Sun-Nor(688621.SH): Net income in the first three quarters was 0.208 billion yuan, a year-on-year increase of 21.4%.
Gelonghui October 28th | Sunshine Norh Pharmaceutical (688621.SH) announced the third quarter report for 2024, with the company's revenue for the first three quarters of 0.917 billion yuan, a year-on-year increase of 32.47%; net income attributable to shareholders of the listed company was 0.208 billion yuan, a year-on-year increase of 21.4%; basic earnings per share was 1.85 yuan.
Yangguang Nuohuo (688621.SH) announced its performance for the first three quarters, with a net income of 0.208 billion yuan, an increase of 21.40% year-on-year.
Sunno Pharmaceutical (688621.SH) disclosed its third quarter report for 2024, achieving operating income in the first three quarters...
No Data